Literature DB >> 34732895

Tumour DDR1 promotes collagen fibre alignment to instigate immune exclusion.

Xiujie Sun1, Bogang Wu1, Huai-Chin Chiang1, Hui Deng2, Xiaowen Zhang1, Wei Xiong2, Junquan Liu2, Aaron M Rozeboom3, Brent T Harris3, Eline Blommaert4, Antonio Gomez5, Roderic Espin Garcia4, Yufan Zhou6, Payal Mitra7, Madeleine Prevost1, Deyi Zhang8, Debarati Banik1, Claudine Isaacs3, Deborah Berry3, Catherine Lai3, Krysta Chaldekas3, Patricia S Latham9, Christine A Brantner10, Anastas Popratiloff10, Victor X Jin6, Ningyan Zhang2, Yanfen Hu7, Miguel Angel Pujana11, Tyler J Curiel12, Zhiqiang An13, Rong Li14.   

Abstract

Immune exclusion predicts poor patient outcomes in multiple malignancies, including triple-negative breast cancer (TNBC)1. The extracellular matrix (ECM) contributes to immune exclusion2. However, strategies to reduce ECM abundance are largely ineffective or generate undesired outcomes3,4. Here we show that discoidin domain receptor 1 (DDR1), a collagen receptor with tyrosine kinase activity5, instigates immune exclusion by promoting collagen fibre alignment. Ablation of Ddr1 in tumours promotes the intratumoral penetration of T cells and obliterates tumour growth in mouse models of TNBC. Supporting this finding, in human TNBC the expression of DDR1 negatively correlates with the intratumoral abundance of anti-tumour T cells. The DDR1 extracellular domain (DDR1-ECD), but not its intracellular kinase domain, is required for immune exclusion. Membrane-untethered DDR1-ECD is sufficient to rescue the growth of Ddr1-knockout tumours in immunocompetent hosts. Mechanistically, the binding of DDR1-ECD to collagen enforces aligned collagen fibres and obstructs immune infiltration. ECD-neutralizing antibodies disrupt collagen fibre alignment, mitigate immune exclusion and inhibit tumour growth in immunocompetent hosts. Together, our findings identify a mechanism for immune exclusion and suggest an immunotherapeutic target for increasing immune accessibility through reconfiguration of the tumour ECM.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34732895      PMCID: PMC8839149          DOI: 10.1038/s41586-021-04057-2

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  15 in total

Review 1.  Matrix proteoglycans in tumor inflammation and immunity.

Authors:  Gauri Deb; Alexander Cicala; Athanasios Papadas; Fotis Asimakopoulos
Journal:  Am J Physiol Cell Physiol       Date:  2022-07-25       Impact factor: 5.282

2.  Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis.

Authors:  Yoshinobu Saito; Ajay Nair; Dianne H Dapito; Le-Xing Yu; Aveline Filliol; Aashreya Ravichandra; Sonakshi Bhattacharjee; Silvia Affo; Naoto Fujiwara; Hua Su; Qiuyan Sun; Thomas M Savage; John R Wilson-Kanamori; Jorge M Caviglia; LiKang Chin; Dongning Chen; Xiaobo Wang; Stefano Caruso; Jin Ku Kang; Amit Dipak Amin; Sebastian Wallace; Ross Dobie; Deqi Yin; Oscar M Rodriguez-Fiallos; Chuan Yin; Adam Mehal; Benjamin Izar; Richard A Friedman; Rebecca G Wells; Utpal B Pajvani; Yujin Hoshida; Helen E Remotti; Nicholas Arpaia; Jessica Zucman-Rossi; Michael Karin; Neil C Henderson; Ira Tabas; Robert F Schwabe
Journal:  Nature       Date:  2022-10-05       Impact factor: 69.504

3.  3D Collagen Fiber Concentration Regulates Treg Cell Infiltration in Triple Negative Breast Cancer.

Authors:  Huan Gao; Qi Tian; Yan Zhou; Lizhe Zhu; Yinliang Lu; Yingying Ma; Jinteng Feng; Yina Jiang; Bo Wang
Journal:  Front Immunol       Date:  2022-06-14       Impact factor: 8.786

Review 4.  Nanomaterial-assisted CRISPR gene-engineering - A hallmark for triple-negative breast cancer therapeutics advancement.

Authors:  Jabeen Farheen; Narayan S Hosmane; Ruibo Zhao; Qingwei Zhao; M Zubair Iqbal; Xiangdong Kong
Journal:  Mater Today Bio       Date:  2022-10-04

5.  Barring the gates to the battleground: DDR1 promotes immune exclusion in solid tumors.

Authors:  Dimitrios L Wagner; Enrico Klotzsch
Journal:  Signal Transduct Target Ther       Date:  2022-01-13

Review 6.  Tumor Microenvironment and Hydrogel-Based 3D Cancer Models for In Vitro Testing Immunotherapies.

Authors:  Chiara Vitale; Monica Marzagalli; Silvia Scaglione; Alessandra Dondero; Cristina Bottino; Roberta Castriconi
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

7.  The Collagen Receptor Discoidin Domain Receptor 1b Enhances Integrin β1-Mediated Cell Migration by Interacting With Talin and Promoting Rac1 Activation.

Authors:  Corina M Borza; Gema Bolas; Xiuqi Zhang; Mary Beth Browning Monroe; Ming-Zhi Zhang; Jens Meiler; Marcin J Skwark; Raymond C Harris; Lynne A Lapierre; James R Goldenring; Magnus Hook; Jose Rivera; Kyle L Brown; Birgit Leitinger; Matthew J Tyska; Markus Moser; Ralph T Böttcher; Roy Zent; Ambra Pozzi
Journal:  Front Cell Dev Biol       Date:  2022-03-03

8.  Discoidin domain receptor 1 is a potential target correlated with tumor invasion and immune infiltration in gastric cancer.

Authors:  Songna Wang; Yuan Fu; Kudelaidi Kuerban; Jiayang Liu; Xuan Huang; Danjie Pan; Huaning Chen; Yizhun Zhu; Li Ye
Journal:  Front Immunol       Date:  2022-07-22       Impact factor: 8.786

9.  Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis.

Authors:  Michael Papanicolaou; Amelia L Parker; Michelle Yam; Elysse C Filipe; Sunny Z Wu; Jessica L Chitty; Kaitlin Wyllie; Emmi Tran; Ellie Mok; Audrey Nadalini; Joanna N Skhinas; Morghan C Lucas; David Herrmann; Max Nobis; Brooke A Pereira; Andrew M K Law; Lesley Castillo; Kendelle J Murphy; Anaiis Zaratzian; Jordan F Hastings; David R Croucher; Elgene Lim; Brian G Oliver; Fatima Valdes Mora; Benjamin L Parker; David Gallego-Ortega; Alexander Swarbrick; Sandra O'Toole; Paul Timpson; Thomas R Cox
Journal:  Nat Commun       Date:  2022-08-06       Impact factor: 17.694

Review 10.  New functions of DDR1 collagen receptor in tumor dormancy, immune exclusion and therapeutic resistance.

Authors:  Audrey Sirvent; Kevin Espie; Evangelia Papadopoulou; Dana Naim; Serge Roche
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.